ISOO

Home

Corporate Advisory Council

ISOO

Purpose:
To promote scientific exchange among health care professionals in oncology, cytotoxic therapy and its impact on the oral environment.

The Society provides a multidisciplinary forum for scientists and clinicians to focus on:

Concepts associated with oral consequences of antineoplastic therapy
Novel strategies germane to cancer research
Educational pursuits related to cancer and cancer therapy oral morbidity
Scientific diversity through collaboration

History of ISOO

2011-2013 Board of Directors

President: Michael Brennan, DDS, MHS (USA)
President Elect: Richard Logan, BDS, MDS, PhD, FFOP (Australia)
VP of Communications: Ourania Nicolatou-Galitis, DDS, MSc, Dr Dent (Greece)
Secretary: Sharon Elad, DMD, MSc (USA)
Treasurer: Janet Fulton, PhD, RN, ACNS-BC, FAAN (USA)
MASCC Liaison: Joel Epstein DMD, MSD, FRCD(C), FRCSEd (USA)
Immediate Past President: Deborah B. McGuire, PhD, RN, FAAN (USA)
At Large Members: Allan Hovan, DMD, MSD, (FRCD) (Canada), Karis Kin Fong Cheng, RN. PhD (Singapore)

Oral Care Study Group
The Oral Care Study Group's (OCSG) new project focused on chronic graft versus host disease (cGVHD) was launched. >>Read More

MASCC Study Group Chairs Lead First of it's Kind Study in Oral Complications of Radiotherapy

Oral Care Surveys

Publications
ISOO Annual Newsletter alt December 2012

A summary of the prevalence of the oral complications reviewed as well as the management recommendations:
Summary of the Oral Complications Systematic Reviews ( PDF, 140 KB)

Management Recommendations - Summary of Evidence Table ( PDF, 64 KB)

Evidence-Based Management Strategies for Oral Complication from Cancer Treatment - ( PDF, 4.7 MB)

International Conference: Oral Complications of Emerging Cancer Therapies April 14-15, 2009 Bethesda, Maryland USA Report authored by Jean Klastersky ( PDF, 100 KB) MD Professor, University of Brussels Chief of Medicine Service, Institut Jules Borde Brussels, Belgium.

ISOO Logo Toolkit